In this issue:
DREAMM-7: Belantamab mafodotin bests daratumumab in RRMM
Front-line extended dosing belamaf + IMiD combo safe in transplant-ineligible disease
Daratumumab + VCd may be a front-line option for transplant-ineligible MM
CASSIOPEIA: PFS benefit to daratumumab in induction, consolidation and maintenance
EVIDENCE – is 12-month MRD status a valid surrogate for survival?
Baseline immune fitness impacts response to teclistamab
Antigen escape is a shared mechanism of resistance to BCMA-directed therapies
Efficacy and safety of factor Xa inhibitors vs warfarin in patients on IMiD therapy
Improvements in outcomes after ASCT over the last 30 years
Please login below to download this issue (PDF)